Zydus Cadila expects to launch its first wave of products in Mexico – one of its future strategic "home markets" – next month, a top executive at the Indian firm has told Scrip. Zydus' push into Mexico comes amid the implementation of a string of favorable regulatory reforms in the pharmaceutical segment by the Latin American nation over the recent past.
Zydus moves into Mexico with first launches
Zydus Cadila expects to launch its first wave of products in Mexico – one of its future strategic "home markets" – next month, a top executive at the Indian firm has told Scrip. Zydus' push into Mexico comes amid the implementation of a string of favorable regulatory reforms in the pharmaceutical segment by the Latin American nation over the recent past.
More from New Products
More from Scrip
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.